자료문의: 02 703 5000        
all of these words any of these words

제한도니 공중보건 예산 및 제약 산업 - 업계 조사를 통한 전문가 패널 뷰 제공 2018
Constrained Public Healthcare Budgets and the Pharmaceutical Industry - Featuring Expert Panel Views From Industry Survey, 2018
◇발행처: GBI    ◇발행일: 2018년 11월   ◇가격: $2,995[PDF]    ◇페이지수: 쪽   
-> 전체보기
재생 의료에 있어서의 임상 연...

68% 할인.
기타할인자료 문의
info@oic.co.kr

목차
요약
목록으로 돌아가기      
 
    

EXECUTIVE SUMMARY

INTRODUCTION
2.1 Global Healthcare Expenditure to Reach $9.17 Trillion by 2020
2.2 US Healthcare Expenditure Consistently Higher Than Other Major Markets
2.3 Factors Contributing to Constrained Healthcare Budgets
2.4 GBI Research Industry Survey: Most Important Factors Constraining Healthcare Budgets I
2.5 GBI Research Industry Survey: Therapy Areas Contributing to Constrained Healthcare Budgets I
2.6 How Do Constraining Healthcare Budgets Impact the Pharmaceutical Industry?

LANDSCAPE
3.1 Pharma in a Changing Environment I
3.2 Current Landscape in Key Mature Markets I
3.3 Current Landscape in Key Emerging Markets I
3.4 GBI Research Industry Survey: Pharmaceutical Pricing and Reimbursement Policies in Europe
3.5 GBI Research Industry Survey: Pharmaceutical Pricing and Reimbursement Policies in the US
3.6 GBI Research Industry Survey: Pharmaceutical Pricing and Reimbursement Policies in the Asia-Pacific

MAIN POLICIES APPLIED IN KEY MARKETS
4.1 Main Pricing and Reimbursement Policies Applied in Key Markets II
4.2 Health Technology Assessment Overview
4.3 Heterogeneity in Health Technology Assessment ‘Value’
4.4 GBI Research Industry Survey: Future Health Technology Assessment Evaluation Criteria in Europe
4.5 GBI Research Industry Survey: Future Health Technology Assessment Evaluation Criteria in US
4.6 GBI Research Industry Survey: Future Health Technology Assessment Evaluation Criteria in Asia-Pacific
4.7 Overview of Managed Entry Agreements (MEA)
4.8 GBI Research Industry Survey: Future of Managed Entry Agreements in Europe
4.9 GBI Research Industry Survey: Future of Managed Entry Agreements in the US
4.10 GBI Research Industry Survey: Future of Managed Entry Agreements in Asia-Pacific
4.11 Pros and Cons of Managed Entry Agreements

IMPACT ON PHARMACEUTICAL INDUSTRY
5.1 GBI Research Industry Survey: Impact of Constrained Healthcare Budgets on the Pharmaceutical Industry
5.2 Negative impacts of Constrained Healthcare Budgets
5.3 Impact on R&D
5.4 Future R&D priorities
5.5 Perspective of the Industry on Future R&D Priorities
5.6 Positive Impacts of Constrained Healthcare Budgets
5.7 Impact of FDA reforms

RESPONSE OF PHARMA COMPANIES
6.1 GBI Research Industry Survey: Industry Response
6.2 Strategic Manoeuvres: Mergers and Acquisitions
6.3 Implementation of digital technology
6.4 R&D changes
6.5 Operational changes: Outsourcing
6.6 Payer engagement
6.7 Integrated Care -the Sixth Emerging Business Strategy?

CONCLUSION

BIBLIOGRAPHY

Title: Constrained Public Healthcare Budgets and the Pharmaceutical Industry - Featuring Expert Panel Views From Industry Survey, 2018
 
주의: 로그인 후 바구니에 담거나 구매해 주세요.      
 

 

Healthcare
의약품
복지 관련
통신
전자
중공업
제약
화학
의학
환경
식품
방위산업
기타
   .
   .
   .
   .
   .
   .
   .
   .
ID(email)
Password
비밀번호 분실 회원가입

Copyrightⓒ2018 OIC(Overseas Information Center) All Rights Reserved.
04373 서울시 용산구 이촌로 1(GS한강에클라트) 1121호
E_mail : info@oic.co.kr Tel: 02-703-5000 Fax: 02-714-1109 /개인정보 취급방침